NASDAQ : COAG
Hemab Therapeutics Holdings, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 41.29 USD (Oct 30, 2026, 3:42 PM EDT) · Market cap 1.93B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.91B |
| Enterprise Value | 1.45B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 46.71M |
| Shares Outstanding | 46.71M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +3,083.02% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 44.96% |
| Float | 20.31M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.26 |
| P/TBV Ratio | 4.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 35.85 |
| Quick Ratio | 35.48 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -19.17% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 68,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 37.74 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 66.01 |
| Average Volume (20 Days) | 433,983 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.16M |
| Short Previous Month | 3.39M |
| Short % of Shares Out | 6.77% |
| Short % of Float | 15.56% |
| Short Ratio (days to cover) | 5.27 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -87.19M |
| Pretax Income | -83.17M |
| Net Income | -83.24M |
| EBITDA | -86.89M |
| EBIT | -87.19M |
| Earnings Per Share (EPS) | -$10.06 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 457.46M |
| Total Debt | 1.03M |
| Net Cash | 456.43M |
| Net Cash Per Share | $9.77 |
| Equity (Book Value) | 454.27M |
| Book Value Per Share | 9.73 |
| Working Capital | 451.05M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -77.33M |
| Capital Expenditures | -135,000 |
| Depreciation & Amortization | 300,000 |
| Net Borrowing | -107,000 |
| Free Cash Flow | -77.47M |
| FCF Per Share | -$1.66 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -24.60% |
| FCF Yield | -4.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $62.67 |
| Price Target Difference | 53.34% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |